Multiple 10b5-1/Rule 144 sales reported for LQDA
Serendipity Biopharma LLC and affiliated parties reported multiple Rule 144/10b5-1 dispositions of Common Stock.
Rhea-AI Filing Summary
Serendipity Biopharma LLC and affiliated parties reported multiple Rule 144/10b5-1 dispositions of Common Stock. The excerpt lists scheduled 10b5-1 sales and Rule 144 sales executed between 04/09/2026 and 05/19/2026, with individual transactions commonly of 25,000 shares and reported dollar amounts per trade. The filings identify a broker-dealer intermediary as Morgan Stanley Smith Barney LLC.
Positive
- None.
Negative
- None.
Insights
Multiple routine 10b5-1/Rule 144 dispositions were executed across April–May 2026.
Records show repeated scheduled sales labeled as "10b5-1 Sales for SERENDIPITY BIOPHARMA LLC" and one sale attributed to Roger Jeffs. Most trades are sized at 25,000 shares, with varying gross proceeds reported per trade.
The activity is presented as broker-facilitated dispositions via Morgan Stanley Smith Barney LLC. Timing and pricing indicate executions across several dates; these are routine dispositions under specified plans rather than ad hoc open-market trades.
Key Figures
Key Terms
10b5-1 regulatory
Rule 144 regulatory
Broker-dealer financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions does the LQDA Form 144 excerpt show?
Who acted as the broker-dealer for these reported sales (LQDA)?
What are typical trade sizes reported in the excerpt for LQDA?
Do the entries indicate if sales were pre-arranged under a trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.